Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß"), today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Healthcare Conference on Monday, June 10, 2024 at 2:40 p.m. Eastern time.
2024年6月3日，馬薩諸塞州列剋星敦（GLOBE NEWSWIRE）——Keros Therapeutics，Inc.（"Keros"）（納斯達克：KROS）是一家臨床生物製藥公司，專注於發現、開發和商業化針對與轉化生長因子-beta（"TGF-ß"）信號傳導失調相關的多種疾病患者的新型治療方法。今天宣佈，Keros的總裁兼首席執行官Jasbir S. Seehra，博士將於2024年6月10日週一下午2:40在Goldman Sachs第45屆年度醫療保健會議上參加爐邊聊天演示。
A live audio webcast of the fireside chat presentation will be available at and an archived replay will be accessible in the Investors section of the Keros website at for up to 90 days following the conclusion of the event.
爐火聊天演示的現場音頻網絡直播將在以下網址提供，並可在Keros網站的投資者版塊中獲取存檔播放，持續時間爲活動結束後90天。
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, we have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros' lead product candidate, KER-050 (elritercept), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Keros' second product candidate, KER-012 (cibotercept), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros' third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.
關於Keros Therapeutics，Inc.
Keros是一家臨床生物製藥公司，專注於開發和商業化新型治療方法，用於治療與TGF-ß家族蛋白信號傳導失調相關的多種疾病患者。我們是TGF-ß家族蛋白的作用領域的領導者，這些蛋白是多種組織的生長、修復和維護的主要調節因子，包括血液、骨、骨骼肌、脂肪和心臟組織。憑藉這種理解，我們已經發現並正在開發具有潛在意義和潛在疾病改善益處的蛋白質治療方法。 Keros的首個產品候選藥物KER-050（elritercept）正在開發用於治療缺少血細胞或細胞減少症，包括骨髓增生異常綜合徵患者和骨髓纖維化患者的貧血和血小板減少。 Keros的第二個產品候選藥物KER-012（cibotercept）正在開發用於治療肺動脈高血壓和心血管疾病。 Keros的第三個產品候選藥物KER-065正在開發用於肥胖症和神經肌肉疾病的治療。
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
投資者聯繫人：
Justin Frantz
jfrantz@kerostx.com
617-221-6042
譯文內容由第三人軟體翻譯。